Leukocyte Adhesion Deficiency Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
| Enrolling by invitation |
NCT06282432 -
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
|
||
| Completed |
NCT01917708 -
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
|
Phase 1 | |
| Completed |
NCT01998633 -
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
|
Phase 2 | |
| Recruiting |
NCT05754450 -
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
|
Phase 3 |